尔康制药控股股东帅放文拟减持不超4200万股，占总股本2.04%

Group 1 - The core point of the news is that Hunan Erkang Pharmaceutical Co., Ltd. announced a pre-disclosure regarding the reduction of shares by its controlling shareholder, Shuai Fangwen, due to personal funding needs [1][2]. Group 2 - Shuai Fangwen holds 853,574,906 shares, accounting for 41.38% of the company's total share capital [2]. - The reduction plan details include a maximum reduction of 42,000,000 shares, which represents 2.04% of the total share capital, within a specified period from October 29, 2025, to January 28, 2026 [2]. - The reduction will be executed through centralized bidding and block trading, with limits on the total number of shares that can be sold in a 90-day period [2].